arrow
D

Dennis Peters

delft university of technology
H指数:19
被引数:2,576

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
2024-11-080
OA
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment
2024-07-241
PRE
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

MYC是乳腺癌中mTOR抑制剂耐药的临床重要驱动因素

2023-08-291
OAAI
Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
2023-07-141
OAAI
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
2022-07-1922
OAAI
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer

尿路上皮癌的肿瘤免疫景观和三级淋巴结构的结构

2021-12-2025
OAAI
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
2020-10-12261
PREAI
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial (vol 25, pg 920, 2019)
2019-06-1712
OAAI
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

转移性三阴性乳腺癌的免疫诱导策略可增强对PD-1阻滞的敏感性: TONIC试验

2019-05-13643
PREAI
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
2018-09-1189
OAAI
PD-L1 positive tumor-infiltrating lymphocytes and mutational load in breast cancer
2017-07-010
PRE
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients
2016-07-01123
OAAI